Both α2M and CLU have previously been shown to reduce the toxic effects of Aβ oligomers (Fabrizi et al., 2001, Narayan et al., 2014) and reduce the toxicity of CSF from Alzheimer’s disease patients and healthy controls (Drews et al., 2017, Yerbury and Wilson, 2010). The gene discussed is A2M; the disease is early-onset autosomal dominant Alzheimer disease.